| Similar Articles |
|---|
 |
The Motley Fool
April 14, 2005
Rich Duprey |
Mentor the Winner on Implants An FDA panel gives Mentor the right to market breast implants after denying Inamed's application. On the news, Inamed's stock fell by more than 3%, and then nearly 7% in early morning trading.   |
The Motley Fool
December 16, 2005
Stephen D. Simpson |
A Romantic Rectangle in Health Care First Medicis wants Inamed, then Allergan wants Inamed. Now Mentor wants Medicis. Strange days in health care, to be sure. Investors, take note. |
The Motley Fool
January 2, 2004
Dave Marino-Nachison |
Medicis: Skin Is In The drug maker has a strong balance sheet and a commitment to product development. |
The Motley Fool
January 15, 2009
Robert Steyer |
Medicis Tries to Save Face The wrinkle-removal drugmaker hopes it can smooth out a tough economy. |
The Motley Fool
August 4, 2004
Roger Nusbaum |
Inamed Waiting for Good News This multifaceted medical device company, which sells breast implants, awaits an FDA decision. The biggest risk is the stock getting caught in a general health sector downturn. |
The Motley Fool
May 6, 2009
Robert Steyer |
Getting Ahead by Getting Rid of Wrinkles Medicis gets the FDA OK for an anti-wrinkle product as the market for Botox and other cosmetic skin drugs sags. |
The Motley Fool
May 19, 2006
Jim Mueller |
Foolish Forecast: Mentor's Uncertain Results Factors outside of the cosmetic surgery products maker's control are leading to short-term uncertainty. Investors, take note. |
The Motley Fool
December 15, 2003
Alyce Lomax |
No Wrinkles for Medicis Medicis Pharmaceuticals announced that the FDA has approved its injectable wrinkle-filling gel, Restylane. Allergan's Botox has found a new competitor in the fountain-of-youth market. |
The Motley Fool
July 28, 2011 |
Medicis Pharmaceutical Earnings Preview Medicis Pharmaceutical will unveil its latest earnings on Tuesday, August 2. |
The Motley Fool
November 22, 2006
Brian Lawler |
Implant Approval Gives Allergan a Lift The return of silicone breast implants continues. Shares of Allergan, best known for its Botox wrinkle treatment, were up nearly 8% on the news. |
The Motley Fool
February 28, 2011
Cindy Johnson |
Medicis Pharmaceutical Shares Popped: What You Need to Know Medicis Pharmaceutical Corporation popped 26% in intraday trading today after reporting an inline quarter and announcing a licensing agreement with Teva Pharmaceutical Industries. |
BusinessWeek
April 25, 2005
Catherine Arnst |
Breast Implants: Science vs. Emotion Lobbying and politics are having a huge effect on the debate over whether to allow silicone breast implants back on the market. |
The Motley Fool
March 19, 2009
Brian Orelli |
Teva: An Equal-Opportunity Bully Making money by picking on the little guy, too. |
The Motley Fool
January 23, 2004
Jean Graham |
Keeping Abreast of Implants Inamed's race with Mentor for first rights to the silicone breast implant market hits a snag. |
Chemistry World
September 6, 2012
Andrew Turley |
Valeant buys $2.6bn skincare firm Canadian pharma company Valeant is to buy US firm Medicis in a $2.6 billion deal. Medicis produces prescription dermatology products as well as over the counter products. |
The Motley Fool
August 31, 2007
Rich Smith |
A Healthy Buyback for Medicis? Investors, can Medicis pay its own way? And even if it can, should it? |
The Motley Fool
September 25, 2008
Brian Orelli |
Medicis Restates, Investors Panic Medicis says it'll have to restate earnings. |
The Motley Fool
August 8, 2006
Stephen D. Simpson |
Waiting on Fine Figures From Mentor Flush with cash, medical aesthetics specialist Mentor needs to reinvest in growth. This is a fine company that rarely trades cheap -- investors, take note. |
The Motley Fool
March 15, 2010
Rick Aristotle Munarriz |
4 Dividend Stocks Showing You the Money Staples... Medicis... Applied Materials... Lennox International... |
The Motley Fool
February 9, 2006
Stephen D. Simpson |
Mentor Needs Some Prettying Up Until new products are approved or acquired, the aesthetics and urology company seems stuck in suspended animation. Just standing in place is not going to build much shareholder value. |
The Motley Fool
April 6, 2005
Stephen D. Simpson |
Investing in Controlling Obesity While every investor must do their own due diligence, here is an outline of at least some of the major ways that investors can hope to profit from medical technology aimed at curing, or at least controlling, obesity.. |
